Aphria (TSX: APH) (OTC: APHQF) has filed a Form 40-F that reveals it is intending to list on the New York Stock Exchange:
The company will join an exclusive group of Canadian cannabis producers that currently trades on a major U.S. exchange, including Canopy Growth (TSX: WEED) (NYSE: CGC), and Cronos Group (TSX: CRON) (NASDAQ: CRON) and Tilray (NASDAQ: TLRY), which trade on the NASDAQ. Recently Aurora Cannabis (TSX: ACB) (OTC: ACBFF) disclosed that it will begin trading on the NYSE with the symbol “ACB” later this month. Aleafia (TSXV: ALEF) (OTC: ALEAF) has filed its Form 40-F and intends to trade on the NASDAQ, while it is likely that CannTrust (TSX: TRST) (OTC: CNTTF) and HEXO Corp (TSX: HEXO) (OTC: HYYDF) will list on a major U.S. exchange as well.
Until Cronos Group listed on the NASDAQ earlier this year, no companies growing, processing or selling cannabis had done so with the exception of GW Pharma (NASDAQ: GWPH).
It’s not clear what trading symbol Aphria will use on the NYSE, but it won’t be “APH”, as Amphenol already uses that symbol.
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email
